“No-DAC” simply signals what is absent: this version lacks the Drug-Affinity-Complex, the albumin-binding group found on the other CJC-1295 form.

Because of that, it is more often called Mod GRF 1-29 — Modified Growth-Hormone-Releasing Factor, residues 1 through 29. GRF (growth-hormone-releasing factor) is an older name for GHRH (growth-hormone-releasing hormone), the hypothalamic signal that triggers growth-hormone release. So the name describes a modified 29-amino-acid piece of GHRH.

It is a 29-amino-acid synthetic peptide: the first 29 residues of GHRH carrying four stabilizing substitutions.

The four changes, relative to the natural GHRH(1-29) sequence, are a D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These are the same substitutions used in the DAC form; the only difference is that this version has no albumin-binding group attached, so it does not gain the extended circulating life.

It is a stabilized derivative of native GHRH, whose active 1-29 fragment underlies both this peptide and Sermorelin.

Human GHRH was characterized in 1982, and its first 29 amino acids were found to retain full biological activity — the same fragment marketed decades ago as Sermorelin. The tetrasubstituted version arose from medicinal-chemistry efforts to make that fragment more chemically robust, and it later served as the peptide backbone onto which the DAC group was added to create long-acting CJC-1295.

The substitutions were introduced to fix specific chemical weak points in the natural sequence.

Native GHRH is rapidly clipped by the enzyme DPP-IV at its second residue and is vulnerable to oxidation and rearrangement at other positions. Replacing those residues — a protected D-alanine at position 2, and swaps at positions 8, 15 and 27 — makes the peptide meaningfully more stable than plain Sermorelin. Even so, without the albumin-binding DAC group, its half-life in circulation is still on the order of minutes, which is the defining practical difference between this form and the DAC form.

It is manufactured by solid-phase peptide synthesis.

The 29-residue chain is built stepwise on a resin (SPPS), cleaved, purified by high-performance liquid chromatography, and verified by mass spectrometry. Because there is no conjugation step, the process is simpler than for the DAC form; quality control centers on sequence fidelity and purity.

This is an important honesty point: the published human data on “CJC-1295” describe the DAC form, not this one.

Modified GRF 1-29 has been studied in preclinical settings as a growth-hormone-releasing peptide, but it does not have its own dedicated human clinical trials establishing benefit or safety. Discussions that cite human growth-hormone or IGF-1 responses to “CJC-1295” are generally referring to the long-acting DAC version, which behaves very differently in the body. Treating the two as interchangeable is a common and misleading error.

This material is offered only as a research and educational reference. It is not a drug or supplement, and no dosing, timing, or usage information is provided or implied.